The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2017
Filed:
Jan. 15, 2016
Applicant:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Inventors:
Carl H. June, Merion Station, PA (US);
Bruce L. Levine, Cherry Hill, NJ (US);
David L. Porter, Springfield, PA (US);
Michael D. Kalos, Philadelphia, PA (US);
Michael C. Milone, Cherry Hill, NJ (US);
Assignee:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); C12N 5/0783 (2010.01); C12N 5/22 (2006.01); C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C12N 15/85 (2006.01); C07K 14/705 (2006.01); A61K 48/00 (2006.01); C07K 14/525 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 7/00 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/0011 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); C07K 14/525 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/585 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/80 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2501/515 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15071 (2013.01);
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.